| Today's Edition
Monday June 13th, 2016
Stay ahead of the pack with "The QualityStocks Daily", our summary formatted newsletter
containing stock tips from hundreds of online investment newsletters.
Daily.QualityStocks.net
CV Sciences, Inc. (CVSI)
Today we are reporting on CV Sciences, Inc. (CVSI), here at the QualityStocks Daily Newsletter.
A life science company, CV Sciences, Inc. centers on developing and commercializing novel therapeutics using synthetic Cannabidiol (CBD). The Company operates two divisions - pharmaceuticals and consumer products. These divisions are supported by its medical and scientific advisory board, and state‐of‐the art production facilities. The Company was previously known as CannaVEST Corp. It changed its name to CV Sciences, Inc. in January of this year. CV Sciences is headquartered in Las Vegas, Nevada and the Company lists on the OTCQB.
CV Sciences’ Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine. It is pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications using cannabidiol as the active pharmaceutical ingredient. CV Sciences has attained promising preclinical results in the development of cannabinoid medicines for the treatment of a range of medical conditions.
Its Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Each consumer products brand is backed by a formal safety review, a growing body of case reports, as well as physician’s recommendations.
In addition, CV Sciences manufactures, markets, and sells plant-based CBD products under the PlusCBD brand. This is for a range of market sectors, including nutraceutical, beauty care, specialty foods, and vape.
In December of 2015, CV Sciences acquired CanX, Inc. CanX is a Pre-Clinical drug development enterprise. It is concentrating on significant unmet medical needs. Its initial drug candidate is CVSI-007. CVSI-007 chewing gum combines CBD and Nicotine and it is patent pending.
CV Sciences has put together a qualified and experienced team to lead its drug development program. It includes Chief Medical Officer, Dr. Chris Chapman. Dr. Chapman serves as Chairman and Chief Executive Officer (CEO) of Chapman Pharmaceutical Consulting, Inc. Chapman Pharmaceutical Consulting provides expert medical consultation on the development and management of domestic and international product development programs for biotechnology, pharmaceutical, and medical device products.
The team also includes Ms. Shelly Goodman – Clinical and Regulatory Advisor. Ms. Goodman is the CEO of The FourCe, LLC and is the Head of Global Drug Safety and Pharmacovigilance for Portola Pharmaceuticals, Inc.
CV Sciences, Inc. (CVSI), closed Monday's trading session at $0.41, up 4.46%, on 106,431 volume with 39 trades. The average volume for the last 60 days is 6,701 and the stock's 52-week low/high is $0.10/$1.45.
|
